(NASDAQ: INSM) Insmed's forecast annual revenue growth rate of 51.51% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.15%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.98%.
Insmed's revenue in 2026 is $1,137,635,000.On average, 26 Wall Street analysts forecast INSM's revenue for 2026 to be $400,730,058,005, with the lowest INSM revenue forecast at $355,525,086,884, and the highest INSM revenue forecast at $428,464,508,886. On average, 26 Wall Street analysts forecast INSM's revenue for 2027 to be $651,868,786,455, with the lowest INSM revenue forecast at $552,068,439,584, and the highest INSM revenue forecast at $788,793,988,836.
In 2028, INSM is forecast to generate $855,181,965,748 in revenue, with the lowest revenue forecast at $634,179,884,712 and the highest revenue forecast at $1,096,056,763,557.